Teachers Advisors LLC raised its stake in Omeros Corporation (NASDAQ:OMER) by 7.8% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 68,285 shares of the biopharmaceutical company’s stock after buying an additional 4,951 shares during the period. Teachers Advisors LLC owned 0.16% of Omeros Corporation worth $1,032,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of OMER. Wells Fargo & Company MN boosted its stake in shares of Omeros Corporation by 5.5% in the first quarter. Wells Fargo & Company MN now owns 37,717 shares of the biopharmaceutical company’s stock valued at $571,000 after buying an additional 1,960 shares during the period. American International Group Inc. boosted its stake in shares of Omeros Corporation by 15.2% in the first quarter. American International Group Inc. now owns 24,521 shares of the biopharmaceutical company’s stock valued at $371,000 after buying an additional 3,232 shares during the period. Swiss National Bank boosted its stake in shares of Omeros Corporation by 5.7% in the first quarter. Swiss National Bank now owns 67,100 shares of the biopharmaceutical company’s stock valued at $1,015,000 after buying an additional 3,600 shares during the period. Nationwide Fund Advisors boosted its stake in shares of Omeros Corporation by 6.6% in the first quarter. Nationwide Fund Advisors now owns 70,680 shares of the biopharmaceutical company’s stock valued at $1,069,000 after buying an additional 4,407 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Omeros Corporation by 2.8% in the first quarter. Bank of New York Mellon Corp now owns 225,583 shares of the biopharmaceutical company’s stock valued at $3,411,000 after buying an additional 6,043 shares during the period. 44.93% of the stock is owned by institutional investors and hedge funds.

Omeros Corporation (NASDAQ:OMER) traded up 1.66% during mid-day trading on Friday, reaching $20.81. The company had a trading volume of 493,667 shares. Omeros Corporation has a 12 month low of $7.20 and a 12 month high of $27.09. The stock’s market cap is $932.35 million. The firm’s 50-day moving average price is $21.65 and its 200-day moving average price is $17.38.

Omeros Corporation (NASDAQ:OMER) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.12. The firm had revenue of $17.15 million for the quarter, compared to the consensus estimate of $14.63 million. Omeros Corporation’s revenue for the quarter was up 71.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.32) EPS. Equities research analysts forecast that Omeros Corporation will post ($1.30) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Omeros Corporation (OMER) Stake Increased by Teachers Advisors LLC” was posted by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.watchlistnews.com/omeros-corporation-omer-stake-increased-by-teachers-advisors-llc/1538334.html.

Several brokerages have recently commented on OMER. BidaskClub cut Omeros Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, June 28th. Cantor Fitzgerald cut Omeros Corporation from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $21.00 to $15.00 in a research report on Thursday, May 11th. Maxim Group set a $23.00 target price on Omeros Corporation and gave the stock a “buy” rating in a research report on Monday, May 22nd. Wedbush reaffirmed an “outperform” rating and issued a $47.00 target price on shares of Omeros Corporation in a research report on Wednesday, May 10th. Finally, ValuEngine raised Omeros Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $33.38.

In other Omeros Corporation news, VP Michael A. Jacobsen sold 24,000 shares of the stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $21.20, for a total transaction of $508,800.00. Following the completion of the transaction, the vice president now owns 2,650 shares in the company, valued at approximately $56,180. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Michael A. Jacobsen sold 12,000 shares of the stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $24.95, for a total value of $299,400.00. Following the transaction, the vice president now owns 19,500 shares of the company’s stock, valued at approximately $486,525. The disclosure for this sale can be found here. 13.60% of the stock is currently owned by corporate insiders.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Institutional Ownership by Quarter for Omeros Corporation (NASDAQ:OMER)

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.